Abstract Library

#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression

Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gurevich L, Korsakova N, Kazantseva I, Egorov A, Britvin T,

Keywords: pancreas, neuroendocrine tumors, risk factors, Ki-67, cytokeratin 19,

#755 Surgical Treatment of Pancreatic Neuroendocrine Tumors

Introduction: In the surgical department of First Moscow State Medical University, 335 patients with pNETs were operated on.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Egorov A, Musaev G, Anisimova O, Gurevich L, Kondrashin S,

Keywords: pancreatic neuroendocrine tumors, surgical treatment,

#750 Management of Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor

Introduction: Nonfunctional NETs themselves present in generally two ways, either with symptoms caused by the tumor compression of other organs, or found by imaging test performed for other reasons.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Egorov A, Vasiliev I, Gurevich L, Kondrashin S, Parnova V,

Keywords: pancreas, nonfanctional tumor, metastase,

#689 Immunohistochemical Expression of Somatostatin Receptors 1, 2, 3, and 5 Types (SSR) in Functioning and Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors

Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Gurevich L, Kazantseva I, Panteleeva E, Britvin T, Egorov A,

Keywords: neuroendocrine, tumors, somatostatin, receptor,

#546 Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region

Introduction: The incidence of malignant NETs of the hepatopancreatoduodenal region is currently set at 10-15 cases per 100,000 people. Patient treatment and prognosis differ from those with adenocarcinoma.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Egorov A, Musaev G, Kondrashin S, Gurevich L, Fominyh E,

Keywords: malignant, neuroendocrine tumor, surgery,